CanSense is a company that specializes in cancer diagnostics. They offer a simple blood test that can detect bowel cancer early. The test is non-invasive and reduces colonoscopies. Bowel (colorectal) cancer is the second most common cancer globally.
However, they are a developer of an inexpensive and scalable blood test intended for early diagnosis of bowel cancer.
However, they are a developer of an inexpensive and scalable blood test intended for early diagnosis of bowel cancer.
Location: United Kingdom, England, Wales
Employees: 1-10
Total raised: $1.78M
Founded date: 2018
Founders name: Cerys Jenkins
Founders Related Locations: United Kingdom; United Kingdom, Scotland, Glasgow; United Kingdom, Wales, Swansea
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.03.2023 | Seed | $1.78M | Mercia Ass... |
Persons 5
| Date | First Name | Last Name | Title | Location | |||
| - | Adam | Bryant | Chief Exec... | linkedin.c... | - | A*********... | - |
| - | Peter | Dunstan | - | linkedin.c... | - | p*********... | - |
| - | Dean | Webster | - | linkedin.c... | - | d*********... | - |
| - | Justin | John | - | linkedin.c... | - | j*********... | - |
| - | Cerys | Jenkins | Co-Founder... | linkedin.c... | - | - | United Kin... |
Mentions in press and media 4
| Date | Title | Description |
| 09.01.2024 | GP finger-prick blood test could transform bowel cancer diagnosis in Wales | Welsh patients are playing a major role in the way that bowel cancer is diagnosed, thanks to a leading research study which aims to improve detection and diagnostics while avoiding invasive procedures like colonoscopies. Professor Dean Harr... |
| 09.03.2023 | Start-up raises £1.5m for blood test to detect early-stage bowel cancer | CanSense – a Swansea company which has developed a blood test that aims to save lives by diagnosing bowel cancer at an early stage – has raised £1.5m from Mercia, the Development Bank of Wales and liquid biopsy company Nonacus. |
| 08.03.2023 | CanSense Raises £1.5M in Funding | CanSense, a Swansea, UK-based developer of blood test to detect early-stage bowel cancer, raised £1.5M in funding. The round was led by Mercia, the Development Bank of Wales, and Nonacus. The company intends to use the funds to further deve... |
| - | CanSense | “CanSense – Innovation in cancer diagnostics” |